BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 35464491)

  • 1. The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.
    Hsu RJ; Yu WC; Peng GR; Ye CH; Hu S; Chong PCT; Yap KY; Lee JYC; Lin WC; Yu SH
    Front Immunol; 2022; 13():832394. PubMed ID: 35464491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
    Pum A; Ennemoser M; Adage T; Kungl AJ
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33445810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines and COVID-19: friends or foes?
    Rokni M; Hamblin MR; Rezaei N
    Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
    Wang J; Jiang M; Chen X; Montaner LJ
    J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible mechanisms responsible for acute coronary events in COVID-19.
    Sheth AR; Grewal US; Patel HP; Thakkar S; Garikipati S; Gaddam J; Bawa D
    Med Hypotheses; 2020 Oct; 143():110125. PubMed ID: 32763657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronavirus disease 2019 and pityriasis rosea: A review of the immunological connection.
    Borgia F; Li Pomi F; Alessandrello C; Vaccaro M; Pioggia G; Gangemi S
    J Dermatol; 2022 Oct; 49(10):948-956. PubMed ID: 35675487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
    Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
    Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical Modeling of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Network with Cytokine Storm, Oxidative Stress, Thrombosis, Insulin Resistance, and Nitric Oxide Pathways.
    Sasidharakurup H; Kumar G; Nair B; Diwakar S
    OMICS; 2021 Dec; 25(12):770-781. PubMed ID: 34807729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of IRAK enzymes as a therapeutic strategy against SARS-CoV-2 induced cytokine storm.
    Mahmoud IS; Jarrar YB; Febrimarsa
    Clin Exp Med; 2023 Oct; 23(6):2909-2923. PubMed ID: 37061574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19.
    Karki R; Kanneganti TD
    J Transl Med; 2022 Nov; 20(1):542. PubMed ID: 36419185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine storm induced by SARS-CoV-2.
    Song P; Li W; Xie J; Hou Y; You C
    Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Profiling of COVID-19 in Correlation with SARS and MERS.
    Khalil BA; Shakartalla SB; Goel S; Madkhana B; Halwani R; Maghazachi AA; AlSafar H; Al-Omari B; Al Bataineh MT
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19: imbalanced cell-mediated immune response drives to immunopathology.
    Wang J; Li Q; Qiu Y; Lu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2393-2404. PubMed ID: 36069182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
    Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
    Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 and Sepsis.
    Koçak Tufan Z; Kayaaslan B; Mer M
    Turk J Med Sci; 2021 Dec; 51(SI-1):3301-3311. PubMed ID: 34590796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.